Actinogen to expand clinical development program of its novel Alzheimer’s drug
Health & Biotech
Special report: It’s another step forward for Alzheimer’s fighter Actinogen, who today announced a series of additional clinical studies with its novel Alzheimer’s treatment.
The announcement comes after the company (ASX:ACW) successfully raised $16.5m through an institutional placement and share purchase plan.
The studies will expand the growing data-set for Actinogen’s lead drug Xanamem and include a target occupancy study to test the effect of different doses of the drug.
Also in the works is a higher dose safety study to allow for higher doses to be used, if required, including in non-Alzheimer’s applications, as well as additional safety toxicology studies that will evaluate the drug over longer treatment periods.
Actinogen is already enrolling patients into its clinical trial XanADu, a randomised, double-blind, multi-centre clinical study comparing Xanamem to placebo in subjects with mild dementia due to Alzheimer’s disease.
It’s the largest trial of this kind to be undertaken to date by an Australian biotech.
In addition to improving the growing data-set on Xanamem, Actinogen says the expansion of its clinical development program will also enable the company to explore new commercialisation opportunities.
It told investors new clinical indications are under evaluation to expand the potential use of Xanamem beyond Alzheimer’s for conditions such as diabetes, depression, Parkinson’s disease, schizophrenia, post-traumatic stress disorder (PTSD) and post myocardial infarction.
Actinogen CEO Bill Ketelbey said the company welcomes the opportunity to strengthen and accelerate its development programs.
“All these studies will provide for an invaluable dataset to enhance the value of Xanamem to prospective future development partners.”
Results from the target occupancy study are expected by the second quarter of 2019, in-line with the expected top-line results for XanADu.
The higher dose safety study and additional safety toxicology studies are expected to begin later this year.
This special report is brought to you by Actinogen Medical.
This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice.
If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.